Enhanced Nitric Oxide-Releasing Materials

增强一氧化氮释放材料

• 批准号: 6896808
• 负责人: Scott I Merz
• 金额: $ 47.88万
• 依托单位: MC3, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-04-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6896808
• 关键词: bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biotechnology; cardiovascular prosthesis; cell adhesion; circulatory assist; medical implant science; nitric oxide; platelet activation; polymers; reducing agents; sheep; surface coating

DESCRIPTION (provided by applicant): The goal of this project is to develop a family of nitric oxide-releasing materials (NORM), formed by adding nitric oxide (NO) donor compounds to polymers. The enhanced NORM developed in Phase I of this effort released NO for a prolonged period of time, at rates exceeding the release of the normal endothelium. The NO donor formulations from Phase I will be combined with commercially-available biopolymers. The resulting NORM will be used to treat prosthetic vascular grafts, which will be tested in long-term implantation experiments in sheep to evaluate the efficacy of the materials in prolonging patency. The goal of the project is to focus on developing a prosthetic vascular graft with improved long-term patency as a commercial application of NORM. The advances in NORM technology achieved in pursuit of this goal is expected to lead to other applications of this technology. If successful, NORM technology has the potential to contribute substantially to the field of prosthetic vascular grafts. The number of grafts implanted for hemodialysis access alone is a sizeable and growing market. Failure rates with prosthetic grafts are approximately 40% after one year for lower extremity bypass and hemodialysis grafts. Early thrombosis is common, as is long-term failure due to intimal hyperplasia. Nitric oxide released from NORM may potentially contribute to preventing short- and long-term failure modes. A pilot study showed promising results for short-term benefits.

描述（由申请人提供）： 该项目的目标是开发一系列一氧化氮释放材料 (NORM)，通过向聚合物中添加一氧化氮 (NO) 供体化合物而形成。这项工作的第一阶段开发的增强型 NORM 会长时间释放 NO，其释放速率超过正常内皮细胞的释放速率。第一阶段的 NO 供体配方将与市售生物聚合物相结合。由此产生的 NORM 将用于治疗人工血管移植物，并将在绵羊身上进行长期植入实验，以评估材料在延长通畅性方面的功效。该项目的目标是专注于开发一种具有改善的长期通畅性的人工血管移植物，作为 NORM 的商业应用。为实现这一目标而取得的 NORM 技术进步预计将导致该技术的其他应用。 如果成功，NORM 技术有可能为人工血管移植领域做出重大贡献。仅用于血液透析的植入移植物的数量就是一个相当大且不断增长的市场。下肢搭桥术和血液透析移植术一年后的失败率约为 40%。早期血栓形成很常见，内膜增生导致的长期衰竭也很常见。 NORM 释放的一氧化氮可能有助于防止短期和长期故障模式。一项试点研究显示出有希望的短期效益结果。